Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00734435 · ClinicalTrials.gov registry record · Phase 2
Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects
A Phase 2 study, sponsored by Orexigen Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT00734435 is a Phase 2 study that was terminated before completion, run by Orexigen Therapeutics. The registered enrollment target is 26 participants.
The verdict
NCT00734435, a Phase 2 study, was terminated before completion, sponsored by Orexigen Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if zonisamide SR will prevent weight gain in schizophrenic subjects who take olanzapine (Zyprexa)
Interventions
- DRUG zonisamide SR plus olanzapine
- DRUG Placebo plus olanzapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2008-09 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00734435
The ClinicalTrials.gov registry entry for NCT00734435 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Orexigen Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which zonisamide SR plus olanzapine is the first listed.
NCT00734435 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00734435 about?
NCT00734435 is a clinical study titled "Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects". The purpose of this study is to determine if zonisamide SR will prevent weight gain in schizophrenic subjects who take olanzapine (Zyprexa)
What is the current status of trial NCT00734435?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2008-09. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00734435?
The interventions under investigation include: zonisamide SR plus olanzapine (DRUG), Placebo plus olanzapine (DRUG).
Who is sponsoring clinical trial NCT00734435?
This trial is sponsored by Orexigen Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.